Holen Sie sich die Stockscreener-App
6.01
0.83%
-0.05
Handel nachbörslich:
6.02
0.010
+0.17%
Schlusskurs vom Vortag:
$6.06
Offen:
$6.3
24-Stunden-Volumen:
22,157
Relative Volume:
0.22
Marktkapitalisierung:
$103.24M
Einnahmen:
$35.58M
Nettoeinkommen (Verlust:
$-17.89M
KGV:
-8.8084
EPS:
-0.6823
Netto-Cashflow:
$-17.74M
1W Leistung:
+7.51%
1M Leistung:
-13.90%
6M Leistung:
-10.43%
1J Leistung:
-1.75%
1-Tages-Spanne:
$6.01
$6.30
1-Wochen-Bereich:
$5.48
$6.30
52-Wochen-Spanne:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
6.01 | 104.10M | 35.58M | -17.89M | -17.74M | -0.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Hochstufung | Needham | Hold → Buy |
| 2023-03-22 | Eingeleitet | Jefferies | Buy |
| 2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-24 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-24 | Eingeleitet | Needham | Buy |
| 2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
VRCA Assumed by HC Wainwright & Co. -- Buy Rating Announced - GuruFocus
Number of shareholders of Verrica Pharmaceuticals Inc. – LSX:A41A98 - TradingView
Verrica Expands YCANTH Sales as Wart Trials Advance - MyChesCo
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: Verrica Pharmaceuticals Q1 2026 shows revenue growth - Investing.com Nigeria
Verrica Pharmaceuticals Q1 earnings call highlights - MSN
VRCA Stock Price, Quote & Chart | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals Inc. (VRCA) reports Q1 loss, tops revenue estimates - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2026 Earnings Call Transcript - Insider Monkey
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call - Sahm
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Sahm
Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives - Sahm
Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially - MSN
Verrica (VRCA) Q1 2026 Earnings Transcript - AOL.com
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 2026 Growth for YCANTH - GuruFocus
Verrica Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Q1 Earnings Call Highlights - inkl
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 Revenue Growth - GuruFocus
VRCA: Record Q1 growth for YCANTH, pipeline progress, and global expansion drive positive outlook - TradingView
Verrica Pharmaceuticals 1Q Rev $5.02M >VRCA - Moomoo
Verrica Pharmaceuticals (VRCA) Q1 2026: EPS Not Disclosed (Est - GuruFocus
VRCA: Record YCANTH growth, robust pipeline progress, and strong cash position highlight Q1 2026 - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
[10-Q] Verrica Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum - ChartMill
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Verrica (NASDAQ: VRCA) Q1 revenue hits $5.0M as YCANTH demand grows - Stock Titan
Earnings Call Summary | Verrica Pharmaceuticals(VRCA.US) Q1 2026 Earnings Conference - 富途牛牛
MSN Money - MSN
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Positive Phase II data on Verrica and Lytix’ ruxotemitide in BCC - The Pharma Letter
Lytix Biopharma ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma - Finansavisen
In 9 patients, Verrica's skin cancer drug shrank untreated tumors 67% - Stock Titan
Verrica Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 - The Manila Times
Verrica schedules May 12 webcast for Q1 results and update - Stock Titan
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ... - Caledonian Record
Verrica Pharmaceuticals to Report First Quarter 2026 - GlobeNewswire
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting - Yahoo Finance
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):